# OnCo record nct07633873 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07633873/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07633873", "NCT07633873" ;
  schema:name "SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST"@en ;
  schema:description "A phase 3 trial of tislelizumab, paclitaxel / nab-paclitaxel, cisplatin and carboplatin in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07633873/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07633873> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/cspc/> .